NCT02594098 - Secukinumab for Treatment of Atopic Dermatitis | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2015

Primary Completion Date

January 30, 2018

Study Completion Date

January 30, 2018

Conditions

Atopic Dermatitis

Interventions

DRUG

Secukinumab

At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.

DRUG

Placebo

At Weeks 0, 1, 2, 3, 4 and every 2 weeks thereafter through and including Week 12 in phase 1 of the study.

Trial Locations (1)

Icahn School of Medicine at Mount Sinai, New York